Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

What is the role of autologous stem cell transplant in multiple myeloma?

Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical...

What is the role of autologous stem cell transplant in multiple myeloma? ( Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA )

Once-weekly carfilzomib combined with lenalidomide and dexamethasone for...

Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical...

Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multiple myeloma ( Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA )

PLEIADES: Daratumumab combinations for multiple myeloma

Dr Ajai Chari - Mount Sinai, New York City, USA

PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory...

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

Treatment options for high risk relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Introduction of the biosimilar trastuzumab and its impact on patients and...

Geoff Saunders - The Christie NHS Foundation Trust, Manchester, UK

Introduction of the biosimilar trastuzumab and its impact on patients and services ( Geoff Saunders - The Christie NHS Foundation Trust, Manchester, UK )

Practical guidance on the assessment of biosimilar monoclonal antibodies: A...

Prof Diana Lüftner - Charité University Hospital, Berlin, Germany

Practical guidance on the assessment of biosimilar monoclonal antibodies: A physician's perspective ( Prof Diana Lüftner - Charité University Hospital, Berlin, Germany )

Continuous treatment versus fixed duration therapy: Using real-world evidence...

Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin

Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma ( Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin )

Transitioning from bortezomib to ixazomib in patients with multiple myeloma

Dr Habte Yimer - Texas Oncology, Tyler, USA

Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )

Evaluating treatment options for acute myeloid leukaemia

Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA

Evaluating treatment options for acute myeloid leukaemia ( Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA )

More from ecancer